title: Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C.
abstract: OBJECTIVE
  Certain statins interfere with the mechanism of the hepatitis C virus replication. We aimed at studying the effect of statins on the level of viremia and of the pro-and anti-inflammatory cytokines in the patients with chronic hepatitis C.
  
  
  METHODS
  We took in our study all the patients with chronic hepatitis C placed in the evidence of the clinics of internal medicine of the Emergency County Clinical Hospitals of Braşov, Oradea and Sibiu, who had been identified with viremias. The patients were treated with fluvastatin 40 mg/day or lovastatin 20 mg/day for 28 days. The level of viremia, hemoleukogram, hepatic biochemical tests and the pro and anti-inflammatory hepatic cytokines were analysed before and after the treatment. The final results were compared with the initial ones, as well as between the 2 groups.
  
  
  RESULTS
  Regarding those 99 analysed patients, the initial average viremia was of 2376074 +/- 3427596 UI/ml, while the final one was of 1321136 +/- 1343570 UI/ml (p = 0.000987). Both, in the group treated with lovastatin, as well as in that treated with fluvastatin, the decrease of viremia was significant from the statistics point of view (p = 0.032, respectively p = 0.00092). Lovastatin administration resulted in the significant decrease of the pro-inflammatory cytokines IL-6 and TNF-alfa, while that of fluvastatin brought about the significant decrease of the serum levels of IL-6, IL-8 and TNF-alfa. There were no significant differences, statistically speaking, between the 2 determinations, regarding the levels of IL-10 (anti-inflammatory cytokine) and those of erythropoietin. Transaminases average level did not vary significantly after those 4 weeks of statins treatment.
  
  
  CONCLUSIONS
  Lovastatin and fluvastatin, significantly decrease the level of viremia, of IL-6 and TNF-alpha in the patients with chronic hepatitis C.
authors.affiliation: "Lucian Blaga" University of Sibiu, Romania. romeomihaila@yahoo.com
authors.forename: Romeo
authors.initials: R
authors.lastname: Mihăilă
authors.forename: Laurentiu
authors.initials: L
authors.lastname: Nedelcu
authors.forename: Ovidiu
authors.initials: O
authors.lastname: Frăţilă
authors.forename: Elena Cristina
authors.initials: EC
authors.lastname: Rezi
authors.forename: Carmen
authors.initials: C
authors.lastname: Domnariu
authors.forename: Ramona
authors.initials: R
authors.lastname: Ciucă
authors.forename: Alina Viorica
authors.initials: AV
authors.lastname: Zaharie
authors.forename: Ariela
authors.initials: A
authors.lastname: Olteanu
authors.forename: Liliana
authors.initials: L
authors.lastname: Bera
authors.forename: Mircea
authors.initials: M
authors.lastname: Deac
authors.forename: Rodica
authors.initials: R
authors.lastname: Mihăilă
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D016207:Cytokines / Q000097:blood*; D004452:Echocardiography; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014766:Viremia / Q000188:drug therapy*
chemical_list: D016207:Cytokines; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D000077340:Fluvastatin; D008148:Lovastatin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase